Tags : NantKwest


ProMab Biotechnologies Signs Worldwide License Agreement with NantKwest to Develop

Shots: ProMab Biotechnologies signs WW license agreement with NantKwest to develop Ab targeting B-Cell Maturation Antigen (BCMA) against myeloma ProMab Biotechnologies get an option to add five chimeric antigen receptor (CAR) targeting sequences based on natural killer (NK) cell therapies NantKwest’s lead NK cell platform includes haNK and taNK designed to induce cell death by […]Read More